Intermittent G-CSF in Patients With Breast Cancer Receiving Adjuvant Docetaxel, Doxorubicin, and Cyclophosphamide (TAC)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2016
To compare the efficacy and safety of Day 2 (D2) once a cycle pegfilgrastim with Intermittent Every Other Days of 5 Shot (D3-11) filgrastim in early breast cancer patients treated with adjuvant Docetaxel, Doxorubicin, and Cyclophosphamide (TAC) regimen
Epistemonikos ID: 66d75872ba97229aa11867bbfc5d92f95f056f15
First added on: May 12, 2024